Literature DB >> 27158377

Relation between anti-atherosclerotic effects of IRAK4 and modulation of vascular smooth muscle cell phenotype in diabetic rats.

Lijuan Cao1, Defeng Pan2, Dongye Li3, Yanbin Zhang2, Qiuping Chen1, Tongda Xu2, Wenhua Li2, Wanling Wu2.   

Abstract

Deregulation of phenotypic modulation in VSMCs is the initial stage of atherosclerosis, especially in diabetes. Functional deficiency of IRAK4 inhibits the formation of vascular lesions in ApoE-/- mice. Therefore, in this study, we examined the functions of IRAK4 in the regulation of VSMCs differentiation and phenotypic modulation at the levels of transcription and translation in T2D rats. The T2D rat model was generated by feeding a high-fat diet and injecting a low dose of streptozotocin intraperitoneally. VSMCs were isolated from the thoracic aortas of the T2D rats. VSMCs proliferation and migration were measured using water soluble tetrazolium salt-1 assay, 5-ethynyl-29-deoxyuridine staining and migration assay. IRAK4 was knocked down by siRNA and inhibited by an IRAK1/4 inhibitor. The mRNAs and proteins of signal molecules and phenotypic markers were detected by qRT-PCR and western blotting. The results demonstrated that LPS significantly increased viability, cell migration rate and amount of DNA in VSMCs. The IRAK4 inhibitor also reduced LPS-mediated protein expression of myosin heavy chain and nuclear factor κB p65 subunit and increased smooth muscle 22α expression. Moreover, IRAK4 knock-down reduced the LPS-mediated expression of mRNAs for myosin heavy chain, nuclear factor κB p65 subunit, and monocyte chemoattractant protein-1 (MCP-1), but increased the mRNA of smooth muscle 22α in VSMCs. The activation of IRAK4 phenotypically modulated VSMCs from differentiation to dedifferentiation. Inactivation of IRAK4 exerts a protective effect on VSMCs differentiation and inhibits inflammation. IRAK4 could therefore be a target for interventions to prevent and treat the initial phase of atherosclerosis.

Entities:  

Keywords:  IRAK4; MCP-1; Type 2 diabetes rat model; Vascular smooth muscle cells; phenotypic modulation

Year:  2016        PMID: 27158377      PMCID: PMC4846934     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  42 in total

1.  A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat.

Authors:  M J Reed; K Meszaros; L J Entes; M D Claypool; J G Pinkett; T M Gadbois; G M Reaven
Journal:  Metabolism       Date:  2000-11       Impact factor: 8.694

Review 2.  Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis.

Authors:  Teruo Inoue; Kevin Croce; Toshifumi Morooka; Masashi Sakuma; Koichi Node; Daniel I Simon
Journal:  JACC Cardiovasc Interv       Date:  2011-10       Impact factor: 11.195

Review 3.  Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies.

Authors:  Carlos Silvestre-Roig; Menno P de Winther; Christian Weber; Mat J Daemen; Esther Lutgens; Oliver Soehnlein
Journal:  Circ Res       Date:  2014-01-03       Impact factor: 17.367

4.  Inflammasome is a central player in the induction of obesity and insulin resistance.

Authors:  Rinke Stienstra; Janna A van Diepen; Cees J Tack; Md Hasan Zaki; Frank L van de Veerdonk; Deshani Perera; Geoffrey A Neale; Guido J Hooiveld; Anneke Hijmans; Irene Vroegrijk; Sjoerd van den Berg; Johannes Romijn; Patrick C N Rensen; Leo A B Joosten; Mihai G Netea; Thirumala-Devi Kanneganti
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-29       Impact factor: 11.205

Review 5.  Hypoglycemia, diabetes, and cardiovascular disease.

Authors:  Janet K Snell-Bergeon; R Paul Wadwa
Journal:  Diabetes Technol Ther       Date:  2012-06       Impact factor: 6.118

6.  L-ascorbic acid stimulates expression of smooth muscle-specific markers in smooth muscle cells both in vitro and in vivo.

Authors:  Emi Arakawa; Kazuhide Hasegawa; Junko Irie; Shinichi Ide; Junko Ushiki; Kazuo Yamaguchi; Shoji Oda; Yuzuru Matsuda
Journal:  J Cardiovasc Pharmacol       Date:  2003-12       Impact factor: 3.105

7.  [MCPIP1 mediates MCP-1-induced vascular smooth muscle cell proliferation].

Authors:  Yi-Jun Yang; Liu-Song Wu; Bo Shu; Min-Zhang Qian
Journal:  Sheng Li Xue Bao       Date:  2013-12-25

8.  Innate immune interleukin-1 receptor-associated kinase 4 exacerbates viral myocarditis by reducing CCR5(+) CD11b(+) monocyte migration and impairing interferon production.

Authors:  Alan Valaperti; Mototsugu Nishii; Youan Liu; Kotaro Naito; Megan Chan; Liyong Zhang; Carsten Skurk; Heinz-Peter Schultheiss; George A Wells; Urs Eriksson; Peter P Liu
Journal:  Circulation       Date:  2013-09-12       Impact factor: 29.690

9.  Effects of DNA damage in smooth muscle cells in atherosclerosis.

Authors:  Kelly Gray; Sheetal Kumar; Nichola Figg; James Harrison; Lauren Baker; John Mercer; Trevor Littlewood; Martin Bennett
Journal:  Circ Res       Date:  2014-12-18       Impact factor: 17.367

10.  Interleukin-1/toll-like receptor-induced nuclear factor kappa B signaling participates in intima hyperplasia after carotid artery balloon injury in goto-kakizaki rats: a potential target therapy pathway.

Authors:  Xiaotian Zhang; Yi Wang; Wenjing Hu; Dongye Li; Zhongmin Zhou; Defeng Pan; Wanling Wu; Tongda Xu
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

View more
  4 in total

Review 1.  Lipopolysaccharide induced vascular smooth muscle cells proliferation: A new potential therapeutic target for proliferative vascular diseases.

Authors:  Dehua Jiang; Yu Yang; Dongye Li
Journal:  Cell Prolif       Date:  2017-02-02       Impact factor: 6.831

Review 2.  Immunological mechanisms underlying sterile inflammation in the pathogenesis of atherosclerosis: potential sites for intervention.

Authors:  Roland Truong; Finosh G Thankam; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2020-12-21       Impact factor: 4.473

3.  Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia.

Authors:  Xiaoyan Wu; Lin Wang; Yining Qiu; Bingyu Zhang; Zhenhua Hu; Runming Jin
Journal:  Int J Nanomedicine       Date:  2017-10-31

Review 4.  Plant-Derived Products for Treatment of Vascular Intima Hyperplasia Selectively Inhibit Vascular Smooth Muscle Cell Functions.

Authors:  Kang Xu; Mohanad Kh Al-Ani; Xin Pan; Qingjia Chi; Nianguo Dong; Xuefeng Qiu
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-11       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.